SEC Form 4 · accession 0001104659-26-075252
Zenas BioPharma, Inc. · ZBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James P Boylan
Director
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 6:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001953926
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $18.71 | Jun 15, 2026 | A | 18,500 | A | — | Jun 15, 2036 | Common Stock | 18,500 | 18,500 | D |
Explanation of responses
- F1The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service.
- F2The reporting person holds the stock option, and the shares underlying the option, for the benefit of Enavate Sciences, L.P. Accordingly, the reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, if any.